I n 1999, Cryptococcus gattii emerged on Vancouver Island, British Columbia (BC), Canada, among residents, visitors to the island, and domestic and wild animal populations. Disease incidence on Vancouver Island plateaued at 36 cases/million population/year during 2002-2005, markedly higher than rates reported in other C. gattii-endemic areas (1, 2) .
Unlike the closely related species C. neoformans, a common opportunistic pathogen of immunocompromised hosts, C. gattii affects primarily immunocompetent persons. Two C. gattii serotypes, B and C, have been described (3) . The fungus is acquired through inhalation of airborne propagules and may cause pulmonary and central nervous system disease. Activities that disturb colonized soil or trees may increase the likelihood of exposure (4) . Disease acquisition likely also depends on host factors, including underlying lung conditions and oral steroid use (M. Fyfe, unpub. data).
In a study of Vancouver Island human C. gattii serotype B cases from January 1999 through December 2001, infection was most common in men and those >60 years of age. Chest radiograph showed single or multiple pulmonary nodules in 68% of patients. Symptoms included severe cough and shortness of breath, often accompanied by chills, night sweats, and anorexia. Approximately 20% of patients had cryptococcal meningitis (M. Fyfe, unpub. data). The median incubation period was ≈6-7 months (5).
C. gattii has been isolated from more than 10 different native tree species on Vancouver Island and from the surrounding soil and air (6,7; S.E. Kidd et al., in press ). Despite sampling in areas both on and off the island, positive environmental isolates have, until recently, been confined to the Coastal Douglas Fir and very dry Coastal Western Hemlock biogeoclimatic zones along the east coast of Vancouver Island (8, Figure 1 ).
VGIIa and VGIIb are the most commonly identified genotypes among human, animal, and environmental isolates from Vancouver Island (6) . The VGI genotype has been isolated less frequently from clinical and environmental samples (6,9; S.E. Kidd et al., in press Vancouver Island is the largest island on the Pacific Coast of North America, covering 32,000 km 2 , with a population of ≈700,000. It is separated from the BC mainland by the Strait of Georgia, a body of water ≈50 km wide that contains several smaller islands known as the Gulf Islands (Figure 1 ). Travel among Vancouver Island, the BC mainland, and the Gulf Islands is very common, with an estimated 17.3 million passengers transported on BC Ferries' Vancouver Island routes annually (12) .
Until 2004, all human cases of C. gattii infection reported to the British Columbia Centre for Disease Control were among those living on or traveling to Vancouver Island during the year before symptoms appeared. In December 2004, the first evidence of disease in humans without exposure to Vancouver Island or other known C. gattii-endemic areas was detected. This article summarizes the epidemiologic and environmental support for disease acquisition in parts of the BC lower mainland and focal areas of the US Pacific Northwest.
Methods

Human Surveillance
We interviewed persons from whom C. gattii serotype B was cultured through December 31, 2005, and who did not report contact with Vancouver Island or other known disease-endemic areas. We conducted telephone interviews by using a standard questionnaire to assess demographic information, travel history, risk factors for infection, underlying medical conditions, and clinical symptoms. Risk factors and travel exposures were assessed for the 1-year period before the onset of illness (or before diagnosis, in asymptomatic cases). Health authorities in neighboring provinces (Canada) and states (USA), where the disease is not reportable, were provided with case investigation forms and encouraged to investigate cryptococcal disease in immunocompetent persons.
Animal Surveillance
Reports of animal cases were informally collected through veterinary networks in BC. Cases from the United States were reported by state veterinary epidemiologists. Infection in the animals was diagnosed histologically or identified as C. gattii serotype B by culture. None of the animals had traveled to Vancouver Island or other diseaseendemic areas.
Environmental Surveillance
From October 2001 through December 2005, environmental sampling was undertaken in the BC mainland, the BC Gulf Islands, and the US Pacific Northwest. We sampled 22 map grids as defined by the 1:50,000-scale National Topographic System of Canada (NTS) and US Geological Survey (USGS) mapping system. Geographic data were assembled as described elsewhere (S.E. Kidd et al., in press). Purposive sampling was conducted at selected sites and areas surrounding the homes of persons with C. gattii infection, those who reported travel to Vancouver Island and those who did not. Sampled environments included front and back yards, walking trails, public parks, and recreational areas. Trees, small woody debris, soil, air, and water were sampled as described elsewhere (S.E. Kidd et al., in press).
Sample positivity was scored binarily. C. gattii concentration was expressed as CFU/gram, CFU/m 3 , and CFU/ 100 mL in soil, air, and water, respectively. The concentrations of multiple samples were described by the geometric mean and geometric standard deviation. When more than 1 sample was taken from a single sampling point (e.g., the same tree), only the first sample was included.
Identification and Genetic Characterization
We initially cultured the samples on Staib media (13) . Resulting dark brown colonies were grown on canavanineglycine-bromothymol blue (CGB) agar (14) to differentiate C. gattii from C. neoformans and then serotyped (Crypto-check, Iatron Laboratories, Tokyo, Japan).
Molecular types were identified by a previously described PCR-based restriction fragment length polymorphism (RFLP) method (15) , which was adapted for further discrimination of variation within the VGII molecular type (9) . The URA5 gene was amplified as previously described (15) and then completely digested at 37°C in a 20-µL reaction containing 1× NEB2 buffer, 1× bovine serum albumin, and 4 U each of Hha I, Dde I, and BsrG I (New England Biolabs, Inc., Ipswich, MA, USA). RFLP products were subjected to electrophoresis and visualized on a 3% agarose gel prestained with ethidium bromide. Control strains were used for each possible C. gattii RFLP pattern: WM179 (VGI), NIH444 (VGIIa), RB28 (VGIIb), WM161 (VGIII), and WM779 (VGIV). C. neoformans strains WM148 (VNI), WM626 (VNII), WM628 (VNIII), and WM629 (VNIV) were also included.
Multilocus sequence typing was performed for selected isolates by using methods previously described (8) with the use of 2 additional loci, PLB1 and IGS (16) . We isolated total DNA from histopathology specimens (n = 3) by using the DNeasy Tissue kit (QIAGEN Inc., Mississauga, Ontario, Canada). Cryptococcal-specific PCR-RFLP was conducted as described above. The internal transcribed spacer region (ITS1-5.8S-ITS2) was amplified and sequenced for identification of C. gattii-specific polymorphisms (17) .
Results
Epidemiology of Human Infection
Five persons with culture-confirmed C. gattii, 3 in BC and 2 in Oregon, did not report exposure to Vancouver Island or other cryptococcal disease-endemic areas ( Figure 2 ). Case-patients 1 through 4 received a diagnosis or reported symptom onset from September through December 2004. Case-patient 5, who had a fatal infection, received a diagnosis in December 2005.
Case-patient 1 was a 47-year-old man living in BC who was hospitalized with cough, chills, night sweats, nausea, loss of appetite, muscle pain, headache, and neck stiffness. Both lung and brain cryptococcomas were identified. He had chronic hepatitis C infection and a history of drug addiction. At the time of infection, he smoked 20-40 cigarettes/day. His residence, a farmhouse undergoing significant renovations, was located in NTS grid 092G/05 on the coast north of Vancouver. Environmental exposures included yard and landscaping work at this property.
Case-patient 2 was a 48-year-old woman living in BC who experienced shortness of breath, fever, chills, headache, night sweats, loss of appetite, nausea, and muscle pain. A lung mass was identified by computed tomography. She had no known underlying health conditions. She resided on the BC lower mainland within NTS grid 092G/02; her last visit to Vancouver Island was 4 years before the onset of her illness. In the year before onset, considerable deforestation had occurred near her residence to clear land for housing developments. During this period, she also traveled ≈1 day/week to garden centers and nurseries within NTS 092G/02 to obtain shrubs, trees, and new topsoil for yard landscaping she carried out at her residence.
Case-patient 3 was a 73-year-old woman living in BC who had chronic renal failure requiring dialysis and a history of lung disease and breast cancer. She was asymptomatic; a cryptococcal lung nodule was identified radiographically after she had hip surgery in December 2004. No nodule was apparent on imaging conducted <2 months earlier, which suggests recent acquisition. The patient resided in NTS grid 092G/07. She last visited Vancouver Island 14 years before her diagnosis. She had reduced mobility and consequently little outdoor exposure.
Case-patient 4 was a 59-year-old man living in Oregon who began to experience cough, shortness of breath, fever, chills, weight loss, nausea, and muscle pain in December 2004. He had undergone a kidney transplant in September 2003 and reported scarring of lung tissue due to his occupation. His place of residence was located within USGS grid 44123-A1B4. He had not traveled outside Oregon in the year before symptom onset.
Case-patient 5 was an 87-year-old man living in Oregon (USGS grid 45122-C5D8). He was hospitalized in December 2005 with meningitis, accompanied by fever, weight loss, and loss of appetite. His medical history included chronic lymphocytic leukemia, and he had taken oral steroids in the year before diagnosis. He had traveled to parts of Oregon, Washington, and Colorado during his exposure period.
Epidemiology of Off-island Animal Cases
In BC, a retrospective review of companion animal cases identified 8 culture-confirmed serotype B cases, which occurred in a ferret, a llama, and 6 cats. Specimens were collected from December 2003 through December 31, 2005; animal residences were located throughout the BC lower mainland (Figure 2) .
In Washington, 3 cats with cryptococcal disease residing in USGS 48122-G1H4, close to the BC-USA border, were reported from February through June 2005 ( Figure  2 ). All cases were diagnosed by histopathologic examination, and no cultures were obtained.
Environmental Sampling
From October 2001 through December 2005, 3% of 2,033 off-island environmental samples were positive for C. gattii (Table 1) . Swab samples included 45% of samples from trees and other structures (n = 925), 38% from soil (n = 781), 15% from air (n = 304), and 1% from water (n = 23).
Five positive air samples were recovered from 2 focal areas of the lower mainland at 2 different times ( Figure 3 ). The first 2 were collected from air in NTS grid 092G/02 on the same day in October 2002. No other positive samples were detected in 2003 despite further sampling at this site and others. In July 2004, a third positive air sample was collected from grid 092G/02 and 2 more from grid 092G/01. Despite extensive sampling in these areas and other parts of the BC lower mainland (n = 1,140), C. gattii was not isolated from colonized sources such as trees or soil.
Among environmental samples taken outside Vancouver Island, C. gattii was most often recovered from the Gulf Islands (Table 1) . NTS grid 092B/14 had the highest proportion of positive samples (52/220; 24%). Colonized sources were identified from a single Gulf Island within this grid in March, May, and June of 2004. In 2005, positive soil and tree samples were obtained in February, August, September, and October from 3 of the Gulf Islands (NTS grids 092B/14 and 092F/01) and Washington (USGS grid 48122-G1H4). From among 50 samples collected a month apart in Washington within 10 km of the BC border (USGS grid 48122-G1H4), a single soil sample and a swab of a fence post were positive. An additional 27 samples from other sites along the US side of the border (USGS grids 48122-G1H4 and 48122-G5H8) were negative, as were all 197 samples collected from several areas of Oregon (USGS grids 44123-A1B4 and 45122-C5D8). The geometric mean concentration of detected C. gattii among soil and air samples taken from various sites outside Vancouver Island is summarized in Table 2 . Table 3 and Figure 4 summarize the molecular subtyping results for human and animal isolates from persons and animals with no recent exposure to Vancouver Island, as well as environmental isolates obtained from off-island locations.
Molecular Typing Results for Human, Animal, and Environmental Isolates
Of the 5 human cases, 3 were attributed to the VGIIa molecular type, 1 to the VGIIb molecular type, and 1 to the VGI molecular type. However, although all 3 molecular types have been identified among clinical and environmental isolates from Vancouver Island, multilocus sequence typing (MLST) results indicated that both the VGIIa and VGIIb strains from Oregon cases were genetically distinct from previously characterized Vancouver Island isolates (9, 16) . The Oregon case 4 VGIIa isolate differed from Vancouver Island VGIIa at 1 locus, while Oregon case 5 VGIIb differed from Vancouver Island isolates at 4-5 loci, where it was more similar to Vancouver Island VGIIa than VGIIb (Table 4) .
Cryptococcal DNA isolated from the formalin-fixed, paraffin-embedded tissue of 3 cats in Washington belonged to the VGIIa molecular type. MLST profiles could not be determined in these cases because of the relatively poor quality and yield of DNA from the fixed tissue.
Most off-island environmental isolates that were typed belonged to the VGIIa molecular type. These included 4 of the 5 isolates from lower mainland air samples (the fifth could not be separated from contaminants) and 90% of 20 typed isolates from the NTS grid with the highest proportion of positive off-island environmental samples (092B/14). All tested environmental VGIIa isolates from BC and Washington possessed identical MLST profiles to those of representative isolates from Vancouver Island (Table 3) .
Discussion
Surveillance for C. gattii, conducted in BC since the pathogen emerged on Vancouver Island, identified its spread to off-island locations in 2005. To date, 3 humans and 8 animals residing within the BC lower mainland who had not traveled to Vancouver Island or other known cryptococcal disease-endemic areas within the incubation period for disease have been found to have culture-confirmed C. gattii infection. All but 1 case belonged to the VGIIa subtype, the dominant genotype among clinical and environmental isolates from Vancouver Island (6,9,16). Human surveillance findings are supported by a parallel spread of C. gattii to animal populations on the BC mainland and positive air samples in this area. In addition, C. gattii infections with no recent link to Vancouver Island or other disease-endemic areas have been reported in 3 cats in Washington and 2 persons in Oregon. These cases represent the first evidence of local disease acquisition in this part of the United States. One historic case of VGIIa C. gattii (NIH444) was diagnosed in Seattle in the early 1970s; however, residence and travel history for the infected person are unknown (6, 9, 16) .
Before the identification of new disease-endemic areas, all humans with C. gattii infection either lived within or traveled to the Coastal Douglas Fir and very dry Coastal Western Hemlock biogeoclimatic zones (Figure 1) , located along the eastern edge of Vancouver Island. These zones are characterized by warm, dry summers and mild, wet winters and extend into the southern Gulf Islands and the BC lower mainland. Climates with comparable rainfall and temperature extend south into parts of Washington and Oregon in the United States (18). Franklin and Dyrness (19) identified plant communities similar to those in BC in the San Juan Islands and Puget Trough of Washington and the Willamette Valley in Oregon. These ecologic likenesses to BC support the idea that C. gattii may colonize niche areas of the US Pacific Northwest.
Although microclimate similarities exist, we could not determine whether the isolation of C. gattii from areas outside Vancouver Island represents true colonization or transient dispersal of the organism at the time of sampling, such as through wind flow or mechanical vectors/fomites. Despite repeated sampling, no environmental source (e.g., tree, soil) of the VGIIa isolates detected in air on the BC mainland has been found. Either an undiscovered reservoir exists on the BC mainland or detectable airborne C. gattii was aerosolized and dispersed from known colonized sources, such as Vancouver Island or the Gulf Islands. Washington VGIIa environmental isolates, identical by MLST to those from BC, may represent recent dispersal from BC or independent foci of colonization.
Sampling sites on Vancouver Island have shown different patterns of C. gattii colonization over time (4) . The detected concentration of C. gattii in air and soil samples from the BC lower mainland and northern Washington was lower than in samples from Vancouver Island. Based on a comparison of geometric means, the detected C. gattii concentration in air samples from the mainland was 4-fold lower than in Vancouver Island air samples collected at the same time of the year ( Table 2) . C. gattii concentration in soil from northern Washington and 2 of the Gulf Islands was ≈5× lower than in soil from Vancouver Island. Only in a limited area of 1 particular Gulf Island in grid 092B/14 was C. gattii concentration in soil higher (3.3-fold) than in soil from Vancouver Island.
While direct comparisons with infected persons living on or traveling to Vancouver Island are not possible because of the small number of off-island cases, humans affected by C. gattii in off-island environments may have a higher rate of serious underlying health conditions. Among cases in BC and Oregon, persons were affected by renal failure, chronic hepatitis C infection, and cancer (i.e., chronic lymphocytic leukemia, breast cancer). In an agematched case-control study, persons from Vancouver Island with C. gattii infection were not significantly more likely than noninfected island residents to have had cancer (M. Fyfe, unpub. data) or liver disease (L. MacDougall, unpub. data). Persons with compromised immune systems may be more susceptible to infection with C. gattii at the lower concentrations observed in most off-island environments.
Even with ongoing surveillance in BC, the last reported case of symptom onset in a person with C. gattii infection who had not traveled to Vancouver Island was in As on Vancouver Island, C. gattii in off-island areas was first detected in companion animals. Animal cases began to be regularly identified in March 2004, ≈6 months before human illness was reported in this area. As on Vancouver Island and in Australia, cats were affected more often than other companion animals (20, 21) . However, illness occurred in a ferret and llama, rare animals also infected early in the emergence on Vancouver Island, which may suggest that these species are particularly sensitive to infection. Despite substantial underreporting of animal cases, data from Vancouver Island suggest that animal cases exceeded human cases by almost 75%, highlighting their value as a sentinel indicator of disease (20) .
Clinical and environmental isolates from the BC mainland, Gulf Islands, and northern Washington tested by MLST were identical to representative isolates from Vancouver Island at the 6 loci investigated (Table 4 ) (9,16). However, although isolates from the C. gattii human case-patients living in Oregon were typed as VGIIa and VGIIb, MLST analyses indicated that these isolates were genetically distinct from BC and Washington clinical and environmental isolates. A BLAST comparison (www.ncbi.nlm.gov/BLAST) to sequences from previous studies and those represented in the National Center for Biotechnology Information database identified Oregon strains as genotypically unique (6, 16) . We have not identified an environmental source of C. gattii within Oregon or any isolate possessing the same MLST profile as the Oregon clinical strains. Oregon strains could represent an independent population; alternatively, they may have evolved from the VGIIa or VGIIb strains previously described in BC or from VGIIa strains from California (6,9,16), either through random genetic drift or through sexual recombination. Recent studies suggest that samesex mating can occur among cryptococcal isolates and that the VGIIa genotype may have arisen from same-sex mating between a strain of the VGIIb genotype and another unknown strain (16, 22) .
Conclusion
C. gattii infections have been shown in human and animal residents of the BC lower mainland and in Washington and Oregon in the United States, despite no profiles for selected human, animal, and environmental Cryptococcus gattii isolates. A) URA5-RFLP to determine the molecular type using Hha I and Sau96 I endonucleases (14) . B) URA5-RFLP to confirm molecular type and determine VGII subtype, using Hha I, Dde I, and BsrG I endonucleases.
contact with Vancouver Island or other known diseaseendemic areas. These findings may represent an expansion of recognized areas where the disease is endemic.
